|
Lacy, Jill; Loomis, Regina; Grill, Susan et al. (2006) Systemic Bcl-2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV+ nasopharyngeal carcinoma xenografts in SCID mice. Int J Cancer 119:309-16
|
|
Loomis, Regina; Carbone, Rocco; Reiss, Michael et al. (2003) Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab. Clin Cancer Res 9:1931-9
|
|
Kenney, J L; Guinness, M E; Reiss, M et al. (2001) Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) sensitizes EBV-immortalized B cells to transforming growth factor-beta and chemotherapeutic agents. Int J Cancer 91:89-98
|
|
Guinness, M E; Kenney, J L; Reiss, M et al. (2000) Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice. Cancer Res 60:5354-8
|
|
Piche, A; Kasono, K; Johanning, F et al. (1998) Phenotypic knock-out of the latent membrane protein 1 of Epstein-Barr virus by an intracellular single-chain antibody. Gene Ther 5:1171-9
|
|
Kenney, J L; Guinness, M E; Curiel, T et al. (1998) Antisense to the epstein-barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and bcl-2 expression and promotes apoptosis in EBV-immortalized B cells. Blood 92:1721-7
|
|
Curiel, T J; Piche, A; Kasono, K et al. (1997) Gene therapy strategies for AIDS-related malignancies. Gene Ther 4:1284-8
|
